Salarius Pauses Enrollment in Seclidemstat Phase 1/2 Trial

Salarius Pharmaceuticals has paused new patient enrollment in its phase 1/2 clinical trial of seclidemstat for treating people with various forms of sarcoma, after the death of one patient in the trial.

The company notified the FDA of the death, which is now being reviewed by an independent safety review committee.

The trial is aimed at treating Ewing sarcoma, a form of bone cancer, and other sarcomas caused by mutations of FET proteins.

Despite the pause in the study, the company said it plans on releasing interim sarcoma clinical trial results later this year.